Dr. Edith Perez on Etirinotecan Pegol for HER2-Negative Breast Cancer
In Partnership With:
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.
The BEACON trial (BrEAst Cancer Outcomes with NKTR-102) is an important study for refractory HER2-negative breast cancer, says Perez. It looks at the new compound etirinotecan pegol (NKTR-102), a long-acting topoisomerase-1 inhibitor designed for prolonged tumor cell exposure, in comparison to physicians’ choice of treatment.
Related Videos
Related Content
